---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-000684"
form_type: "8-K"
ticker: "SRTS"
cik: "0001494891"
company_name: "Sensus Healthcare, Inc."
filed_at: "2022-01-05T23:59:59+00:00"
generated_at: "2026-06-27T20:34:14.618416+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sensus Healthcare expects record Q4 2021 sales over $25M, profitable Q4 and FY

## Summary
- Expects record Q4 sales; full-year 2021 revenue over $25M.
- Expects positive EBITDA and net income for Q4 and full year.
- Q4 sales include three SRT systems shipped to China.
- Also expects profitability for Q1 2022.
- TransDermal Infusion System featured at Winter Clinical Dermatology Conference on Jan 15.

## SEC filing metadata
- accession: 0001213900-22-000684
- form_type: 8-K
- ticker: SRTS
- cik: 0001494891
- company_name: Sensus Healthcare, Inc.
- filed_at: 2022-01-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1494891/000121390022000684/0001213900-22-000684-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1494891/000121390022000684/ea153545-8k_sensushealth.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-000684
- JSON: https://secwatch.observer/filing/0001213900-22-000684.json
- Plain text: https://secwatch.observer/filing/0001213900-22-000684.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.